| SESSION NAME |
Physicians, Pharmacists, Psychologists, PAs ASAM Maximum CME 33.5 |
Social Workers ASWB Maximum CE Hours 34.5 |
Nurses, NP, APNs |
|
| Pre-Conference Sessions | ||||
| The Certified Medication Assisted Treatment Advocate (CMA) Training Course (Registration Required) | 0.0 | 7.5 | 7.5 | 7.5 |
| Recovery Services - Living Well in Recovery | 3.0 | 3.0 | 3.0 | 3.0 |
| Harm Reduction 101 | 3.0 | 3.0 | 3.0 | 3.0 |
| Innovative Strategies to Expand Access and Integration of Care for Opioid Use Disorder | 3.0 | 3.0 | 3.0 | 3.0 |
| CARF - Accreditation Presentation "What can CARF Accreditation do for you?" | 4.0 | 4.0 | 4.0 | 4.0 |
| Shifting the Landscape: A Statewide Response to the Opioid Epidemic | 3.0 | 3.0 | 3.0 | 3.0 |
| Opioid Maintenance Pharmacotherapy: An 8-Hour Course for Clinicians | 8.0 | 8.0 | 8.0 | 8.0 |
| Maryland’s Peer Recovery Specialist - Innovations in Support | 3.0 | 3.0 | 3.0 | 3.0 |
| SOR II/III Projects in Maryland | 3.0 | 3.0 | 3.0 | 3.0 |
| Eliminating Hepatitis C Among Persons with Opioid Use Disorder | 3.5 | 3.5 | 3.5 | 3.5 |
| Presentations by the World Federation for the Treatment of Opioid Dependence | 0.0 | 4.0 | 0.0 | 4.0 |
| Opioid Use Disorder and the Americans with Disabilities Act: Eliminating Discriminatory Barriers to Treatment and Recovery | 1.5 | 1.5 | 1.5 | 1.5 |
| Practical Applications of Harm Reduction: From SAMHSA to Community | 0.0 | 3.0 | 0.0 | 3.0 |
| TUESDAY | ASAM | ASWB | NEMSD | ADABGA & NAADAC |
| Poster Author Session | 0.0 | 1.25 | 1.25 | 1.25 |
| PL1: Opening Plenary Session: The Power of Collaboration | 1.5 | 1.5 | 1.5 | 1.5 |
| A1: Foundations of Medication Assisted Treatment | 1.5 | 1.5 | 1.5 | 1.5 |
| A2: Systems-Level Partnerships in Implementing Innovative Enhancements in the Treatment of Opioid Use Disorders | 1.5 | 1.5 | 1.5 | 1.5 |
| A3: The Future of Peer-Led Meetings: Successes in Virtual All-Recovery Support Meetings During COVID-19 | 0 | 1.5 | 1.5 | 1.5 |
| A4: Legal and Policy Strategies to Improve Access to Medications for Opioid Use Disorder in the Criminal Legal System | 1.5 | 1.5 | 1.5 | 1.5 |
| A5: Harnessing Your Expertise: AATOD Media Training with Reporting on Addiction | 1.5 | 1.5 | 1.5 | 1.5 |
| #1: Effectively Treating the Aging and Elderly in Opioid Treatment Programs: A Comprehensive Model | 1.5 | 1.5 | 1.5 | 1.5 |
|
#2: A Comparative Effectiveness Trial of Extended-Release Medications with Individuals Leaving Jail: Lessons Learned |
1.5 | 1.5 | 1.5 | 1.5 |
| #3: Hub and Spoke Model Implementation-9 years Later | 1.5 | 1.5 | 1.5 | 1.5 |
| HT1: Recruitment and Retention During a Workforce Crisis | 0.0 | 1.5 | 1.5 | 1.5 |
| HT2: Does Harm Reduction Help or Hurt Individuals with an OUD? | 0.0 | 1.5 | 1.5 | 1.5 |
| HT3: Opioid and Stimulant Use: Provider Experiences and Best Practices | 0.0 | 1.5 | 1.5 | 1.5 |
| HT4: Turning the Tide of Fentanyl | 0.0 | 1.5 | 1.5 | 1.5 |
| HT5: Merging the Cultures of Behavioral Health and Law Enforcement | 0.0 | 1.5 | 1.5 | 1.5 |
| B1: Building Therapeutic Partnerships: The Most Important Evidenced-Based Practice | 1.5 | 1.5 | 1.5 | 1.5 |
| B2: Reverse the Cycle: Peer Interventions & Hospital-Based MAT Induction in Rural Appalachia | 1.5 | 1.5 | 1.5 | 1.5 |
| B3: Building Workforce Capacity to Address Diversity, Equity, and Inclusion: Developing a Shared Language | 1.5 | 1.5 | 1.5 | 1.5 |
| B4: Injectable Opioid Agonist Therapy in a Perinatal Acute Care Setting | 1.5 | 1.5 | 1.5 | 1.5 |
| B5: MAT in Corrections: 5 Years of Increasing Success. A How-To and Why Story | 1.5 | 1.5 | 1.5 | 1.5 |
| OTP Basics for Non-OTP Professionals | 1.5 | 1.5 | 1.5 | 1.5 |
| WEDNESDAY | ASAM | ASWB | NEMSD | ADABGA & NAADAC |
| PL2: Middle Plenary Session: Systemic Approaches to Treating Opioid Use Disorder | 1.5 | 1.5 | 1.5 | 1.5 |
| MAT Policy, Advocacy, and Reform: Being a Voice In a Time of Change | 1.5 | 1.5 | 1.5 | 1.5 |
| International Session | 0.0 | 1.5 | 0.0 | 1.5 |
| C1: Hepatitis C Testing and Treatment in Opioid Treatment Programs | 1.5 | 1.5 | 1.5 | 1.5 |
| C2: Collaborating to Address Systemic Racism in Substance Use Disorder Treatment: Ant-Racist Strategies | 1.5 | 1.5 | 1.5 | 1.5 |
| C3: An Integrated and Collaborative Approach to Addressing Opioid Misuse and Overdose in Anne Arundel County | 1.5 | 1.5 | 1.5 | 1.5 |
| C4: Law and Medicine: Partnerships through the Opioid Response Network | 1.5 | 1.5 | 1.5 | 1.5 |
| C5: Avoiding Burnout and Compassion Fatigue: How Self-Care among Substance Use Professionals Enhances Patient Care | 1.5 | 1.5 | 1.5 | 1.5 |
| D1: Substance Use Disorder in Pregnancy: Treatment throughout the Four Trimesters | 1.5 | 1.5 | 1.5 | 1.5 |
| D2: The Power of Collaboration: Lessons Learned from OTP Partnerships with Massachusetts Jails and Prisons | 1.5 | 1.5 | 1.5 | 1.5 |
| D3: Systems Collaboration for Model Programming and Sustained Change | 1.5 | 1.5 | 1.5 | 1.5 |
| D4: Merging the Cultures of Behavioral Health and Law Enforcement to Create a Collaborative Team to Address Opioid Overdose | 1.5 | 1.5 | 1.5 | 1.5 |
| D5: Civil Rights Protections for Parents in Child Welfare Services and in Recovery from an Opioid Use Disorder | 1.5 | 1.5 | 1.5 | 1.5 |
| THURSDAY | ASAM | ASWB | NEMSD | ADABGA & NAADAC |
| E1: Integrated Treatment of OUD and Co-occurring Mental Health Disorders | 1.5 | 1.5 | 1.5 | 1.5 |
| E2: NJ's Integrated Opioid Treatment and Substance Exposed Infant Program: Improving Outcomes for Pregnant and Postpartum Women and Their Babies | 1.5 | 1.5 | 1.5 | 1.5 |
| E3: Person-Centered OTP Regulations: Opportunities for State-Level Reform | 1.5 | 1.5 | 1.5 | 1.5 |
| E4: Mile Square Methadone Clinic: An Integrated Collaborative Care Model in a Community Federally Qualified Health Center (FQHC) | 1.5 | 1.5 | 1.5 | 1.5 |
| E5: Addressing Barriers to Wellness and Recovery with Medical and Psychiatric Care Co-located in an Opioid Treatment Program | 1.5 | 1.5 | 1.5 | 1.5 |
| F1: Improving Cross-System Collaboration to Reduce Stigma and Increase Access to Medication-Assisted Treatment Services | 1.5 | 1.5 | 1.5 | 1.5 |
| F3: Understanding Potential Legal Liability for Hospitals When Emergency Departments Do Not Offer Evidence-Based Substance Use Disorder Services | 1.5 | 1.5 | 1.5 | 1.5 |
| F4: The Role of Opioid Treatment Programs in Implementing the National Drug Control Strategy | 1.5 | 1.5 | 1.5 | 1.5 |
| F5: Strategic Productivity, Engagement and Retention of Staff | 1.5 | 1.5 | 1.5 | 1.5 |
| PL3: Closing Plenary: The Present and Future of Federal Regulations for Opioid Treatment | 1.25 | 1.25 | 1.25 | 1.25 |